International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 188-193
EFFECTS OF THE LAMIVUDINE 300 MG/DAY PLUS INTERFERON-A 5 MU/DAY THERAPY ON THE HEMATOLOGICAL PARAMETERS IN PATIENTS WITH HBV RELATED CHRONIC ACTIVE HEPATITIS
HANEFİ CEM GÜL1, CAN POLAT EYİGÜN1, VEDAT TURHAN1, İSMAİL YAŞAR AVCİ1
GATA infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, ANKARA
Keywords: chronic hepatitis b, ifn-a, lamivudine, hematological parameters, adverse effect
Interferon a (IFN-a) has been used only alternative for the therapy of patients with Chronic Active Hepatitis B (CAH-B). Unfortunately sustained response were only 25-40%. There are some efforts to increase this rate by using the Nucleoside Analogues (NA) combined with IFN-a. Lamivudine (LAM) (3Õ TC) is one of the NA that gives hopeful results in therapy of CAH-B. The aim of recent study was to evaluate the effects of LAM 150 mg bid orally + IFN-a 5 MU daily subcutaneous therapy on the hematological parameters in patients with CAH-B. The study group consisted of 4 female and 31 male, aged 23 to 49 (mean; 29.71 ± 6.27) and were treated with LAM plus IFN-a for 6 months. Before the therapy, Mean White Blood Cell (MWBC) count was 6.722 ± 1391.1/mm3, Mean Platelet Count (MPC) 202.000 ± 44.536/mm3, Mean Hemoglobin Value (MHV) 15.1 ± 1.3 mg/dl. MWBC count decreased to 3.731 ± 930.4/mm3 at first week, 3.371 ± 701.9/mm3 at second week, 3.525 ± 722.8/mm3 at fourth week, 3.360 ± 633.4/mm3 at third month and 4.491 ± 896.1/mm3 at sixth month of the therapy. MPC decreased to 141.000 ± 37.275/mm3 at first week, 126.000 ± 39.364/mm3 at second week, 119.000 ± 36.150/mm3 at fourth week, 120.000 ± 38.896/mm3 at third month, 138.000 ± 43.362/mm3 at sixth month of the therapy. MHV decreased to 14.7 ± 1.2 mg/dl at first week, 14,1 ± 1.23 mg/dl at second week, 13.7 ± 1.31 mg/dl at fourth week, 13 ± 1.39 mg/dl at third month and 13.2 ± 1.26 mg/dl at sixth month of the therapy. In one patient, WBC count decreased to 1000/mm3 and the therapy was stopped for five days and in this period the dose of 1mg/kg/day of GM-CSF (Granulocyte Monocyte-Colony Stimulating Factor) was administered to this patient. Then the dose of IFN-a has been decreased 5MU three times in a week. In conclusion, LAM 150 mg bid plus IFN-a 5 MU/day combination therapy was found safe and well tolerated in terms of hematological parameters
HANEFİ CEM GÜL1, CAN POLAT EYİGÜN1, VEDAT TURHAN1, İSMAİL YAŞAR AVCİ1
GATA infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, ANKARA
Keywords: chronic hepatitis b, ifn-a, lamivudine, hematological parameters, adverse effect
Interferon a (IFN-a) has been used only alternative for the therapy of patients with Chronic Active Hepatitis B (CAH-B). Unfortunately sustained response were only 25-40%. There are some efforts to increase this rate by using the Nucleoside Analogues (NA) combined with IFN-a. Lamivudine (LAM) (3Õ TC) is one of the NA that gives hopeful results in therapy of CAH-B. The aim of recent study was to evaluate the effects of LAM 150 mg bid orally + IFN-a 5 MU daily subcutaneous therapy on the hematological parameters in patients with CAH-B. The study group consisted of 4 female and 31 male, aged 23 to 49 (mean; 29.71 ± 6.27) and were treated with LAM plus IFN-a for 6 months. Before the therapy, Mean White Blood Cell (MWBC) count was 6.722 ± 1391.1/mm3, Mean Platelet Count (MPC) 202.000 ± 44.536/mm3, Mean Hemoglobin Value (MHV) 15.1 ± 1.3 mg/dl. MWBC count decreased to 3.731 ± 930.4/mm3 at first week, 3.371 ± 701.9/mm3 at second week, 3.525 ± 722.8/mm3 at fourth week, 3.360 ± 633.4/mm3 at third month and 4.491 ± 896.1/mm3 at sixth month of the therapy. MPC decreased to 141.000 ± 37.275/mm3 at first week, 126.000 ± 39.364/mm3 at second week, 119.000 ± 36.150/mm3 at fourth week, 120.000 ± 38.896/mm3 at third month, 138.000 ± 43.362/mm3 at sixth month of the therapy. MHV decreased to 14.7 ± 1.2 mg/dl at first week, 14,1 ± 1.23 mg/dl at second week, 13.7 ± 1.31 mg/dl at fourth week, 13 ± 1.39 mg/dl at third month and 13.2 ± 1.26 mg/dl at sixth month of the therapy. In one patient, WBC count decreased to 1000/mm3 and the therapy was stopped for five days and in this period the dose of 1mg/kg/day of GM-CSF (Granulocyte Monocyte-Colony Stimulating Factor) was administered to this patient. Then the dose of IFN-a has been decreased 5MU three times in a week. In conclusion, LAM 150 mg bid plus IFN-a 5 MU/day combination therapy was found safe and well tolerated in terms of hematological parameters